On October 18, Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial of the company’s spinal cord stem cells in the treatment of ALS at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first six non-ambulatory patients, the trial’s Safety Monitoring Board has unanimously approved moving to the next group of ALS patients, all of whom will be ambulatory.

Recently, BrainStorm Cell Therapeutics, a company based in Israel, announced that they received approval from Israel’s ministry of Health to run a Phase I/II clinical trial of mesenchymal stem cells in ALS patients.  Mesenchymal stem cells are adult stem cells derived from the patient’s own bone marrow.

Click here for the entire article.


%d bloggers like this: